Delaware 150th General Assembly (2019-2020) Status: In Committee Bipartisan · 10 D · 2 R cosponsors

HB 166 — AN ACT TO AMEND TITLE 16 OF THE DELAWARE CODE RELATING TO CHILDHOOD LEAD POISONING PREVENTION ACT.

Last action — Reported Out of Committee (Health & Human Development) in House with 9 On Its Merits

  1. ✓
    Introduced
  2. 2
    In Committee
  3. 3
    Passed House
  4. 4
    Passed Senate
  5. 5
    To Executive
  6. 6
    Enacted

This bill died with 150th General Assembly (2019-2020). It reached “In Committee” and never advanced before the session ended, so it can no longer move — a new version would have to be reintroduced in the current session.

This bill is no longer active — its legislative session has ended, so there are no live odds of enactment. It would have to be reintroduced in the current session to move again.

Summary

At this time, blood lead level screening and testing rates are well below what the Division of Public Health would expect them to be based upon the risk factors that determine when screening or testing is necessary. This bill simplifies the requirements and the process for healthcare providers and eliminates confusion that may be causing the low compliance rate for screening or testing, and defines terms used in the Act. This bill mandates screening, defined as capillary blood test, at 12 and 24 months of age. The bill clarifies insurance coverage for the costs of compliance with the Act. The Division of Public Health is also directed to report on elevated blood lead levels to the General Assembly annually and to develop regulations to implement and enforce the Act within 12 months of being enacted.

Bill Text

Action History

  1. Reported Out of Committee (Health & Human Development) in House with 9 On Its Merits

  2. Introduced and Assigned to Health & Human Development Committee in House

Sponsors

Sponsorship breakdown

Export CSV (upgrade) →

6 sponsors · 17 co-sponsors · 39 not signed on

Sponsors (6)

Co-sponsors (17)

Not signed on (39)

39 members have not signed on to this bill.

Show all 39 →

"Not signed on" means a member has not sponsored or co-sponsored this bill — it does not imply opposition. Members flagged Voted No have a recorded No vote on this bill.

Whip count is in markup. Polling the chamber and every recorded vote this session. Only the first open is slow. It’s instant for you after this. Calling the roll · Tallying · Engrossing

Subjects

public-safety healthcare health-insurance
Cross-referencing the record. Reading this bill against every other bill in the corpus by meaning, not keywords. Only the first open is slow. It’s instant for you after this. Matching · Ranking · Engrossing

Frequently asked questions

What does HB 166 do?
At this time, blood lead level screening and testing rates are well below what the Division of Public Health would expect them to be based upon the risk factors that determine when screening or testing is necessary. This bill simplifies the requirements and the process for healthcare providers and eliminates confusion that may be causing the low compliance rate for screening or testing, and defines terms used in the Act. This bill mandates screening, defined as capillary blood test, at 12 and 24 months of age. The bill clarifies insurance coverage for the costs of compliance with the Act. The Division of Public Health is also directed to report on elevated blood lead levels to the General Assembly annually and to develop regulations to implement and enforce the Act within 12 months of being enacted.
Who sponsors HB 166?
HB 166 is sponsored by Kimberly Williams (Democratic), Michael F. Smith (Republican), Edward S. Osienski (Democratic), Melissa Minor-Brown (Democratic), Debra Heffernan (Democratic), Franklin D. Cooke (Democratic), Nnamdi O. Chukwuocha (Democratic), David L. Wilson (Republican), David P. Sokola (Democratic), Nicole Poore (Democratic), S. Elizabeth Lockman (Democratic), Stephanie L. Hansen (Democratic), Paul S. Baumbach, Sean Matthews, Catherine Cloutier, Earl G. Jaques Jr., Valerie Longhurst, Sherry Dorsey Walker, Anthony Delcollo, David Bentz, Gerald L. Brady, John L. Mitchell, and Michael Ramone.
What is the current status of HB 166?
This bill died with 150th General Assembly (2019-2020). It reached “In Committee” and never advanced before the session ended, so it can no longer move — a new version would have to be reintroduced in the current session.
Where can I track HB 166?
Track HB 166 free on One Click Politics — get push/email alerts when it moves.

Make your voice heard on HB 166

Find the representatives who decide this bill and tell them where you stand — for yourself, or mobilize your whole list in one click with One Click Politics advocacy software.

Find my representatives → Run a campaign

Stay ahead of HB 166

Last checked for changes 2 months ago · updated continuously

One Click Politics tracks every bill in Congress and all 50 states.

Track this bill →